<?xml version="1.1" encoding="UTF-8" standalone="yes"?><xml><head><creation_date>D:20181218144248+01'00'</creation_date><modification_date>D:20181218144248+01'00'</modification_date><initial_authorization>False</initial_authorization><pdf_file>EU-1-04-290_h_a_dec_18.pdf</pdf_file></head><body><section><header>en  
  en</header><p>european 
 commission</p><p>
 brussels, 18.12.2018</p><p>c(2018) 9142 final</p></section><section><header>commission implementing decision of 18.12.2018 
 amending the marketing authorisation granted by decision c(2004)3580 for “alimta - 
 pemetrexed”, a medicinal product for human use</header><p>(text with eea relevance) (only the dutch text is authentic)</p></section><section><header>en</header><p>1</p></section><section><header>en</header></section><section><header>commission implementing decision of 18.12.2018 
 amending the marketing authorisation granted by decision c(2004)3580 for “alimta - 
 pemetrexed”, a medicinal product for human use</header><p>(text with eea relevance) (only the dutch text is authentic) 
 the european commission, 
 having regard to the treaty on the functioning of the european union, 
 having regard to regulation (ec) no 726/2004 of the european parliament and of the 
 council of 31 march 2004 laying down community procedures for the authorisation and 
 supervision of medicinal products for human and veterinary use and establishing a european 
 medicines agency
 1, and in particular article 10 and 28 thereof, having regard to commission regulation (ec) no 1234/2008 of 24 november 2008 
 concerning the examination of variations to the terms of marketing authorisations for 
 medicinal products for human use and veterinary medicinal products
 2, having regard to the changes to the terms of the decision granting the marketing 
 authorisation requested by eli lilly nederland b.v. in accordance with regulation (ec) no 
 1234/2008, 
 having regard to the opinion of the european medicines agency, formulated on 18 october 
 2018 by the committee for medicinal products for human use on the periodic safety update 
 report for this medicinal product, 
 whereas: 
 (1) 
 the placing on the market of the medicinal product &quot;alimta - pemetrexed&quot; was 
 authorised by commission decision c(2004)3580 of 20 september 2004. 
 (2) 
 the marketing authorisation holder submitted a periodic safety update report for this 
 medicinal product. this report was assessed by the pharmacovigilance risk 
 assessment committee as to whether the marketing authorisation concerned should 
 be maintained, varied, suspended or withdrawn. 
 (3) 
 the scientific assessment performed by the committee for medicinal products for 
 human use, the conclusions of which are set out in annex iv to this decision, shows 
 that a decision should be taken amending the marketing authorisation for the 
 medicinal product concerned.</p><p>
 1 oj l 136, 30.4.2004, p. 1. 2 oj l 334, 12.12.2008, p. 7.</p></section><section><header>en</header><p>2</p></section><section><header>en</header><p>(4) the european medicines agency&apos;s opinion is favourable to the variation of the terms 
 of the decision granting the marketing authorisation as submitted by the marketing 
 authorisation holder. 
 (5) 
 decision c(2004)3580 should therefore be amended accordingly. the community 
 register of medicinal products should also be updated. 
 (6) 
 for the sake of clarity and transparency, it is appropriate, following the amendment of 
 part or parts of the annexes, to provide for a consolidated version thereof. the 
 annexes to decision c(2004)3580 should therefore be replaced. 
 (7) 
 the measures provided for in this decision are in accordance with the opinion of the 
 standing committee on medicinal products for human use, 
 has adopted this decision: 
 article 1 decision c(2004)3580 is amended as follows: 1) annex i is replaced by the text set out in annex i to this decision; 
 2) annex ii is replaced by the text set out in annex ii to this decision; 
 3) annex iii is replaced by the text set out in annex iii to this decision. 
 article 2 this decision is addressed to eli lilly nederland b.v., papendorpseweg 83, 3528 bj utrecht, nederland. 
 done at brussels, 18.12.2018</p><p>for the commission</p><p>
 anne bucher</p><p>
 director-general</p></section></body></xml>